|1.||Happe, Antje: 2 articles (03/2015 - 01/2014)|
|2.||Matthes, Harald: 2 articles (03/2015 - 01/2014)|
|3.||Kröz, Matthias: 2 articles (03/2015 - 01/2014)|
|4.||Steele, Megan L: 2 articles (03/2015 - 01/2014)|
|5.||Schad, Friedemann: 2 articles (03/2015 - 01/2014)|
|6.||Axtner, Jan: 2 articles (03/2015 - 01/2014)|
|7.||Chung, Youn-Jee: 1 article (01/2015)|
|8.||Jeung, In-Cheul: 1 article (01/2015)|
|9.||Kim, Mee-Ran: 1 article (01/2015)|
|10.||Kim, Jang-Heub: 1 article (01/2015)|
01/01/2015 - "While previous clinical studies have shown that helixor A to be an effective treatment for endometriosis, little is known about its mechanism of action, or its relationship with immune cells. "
01/01/2015 - "The aim of this study is to investigate the effects of helixor A on Natural killer cell (NK cell) cytotoxicity in endometriosis We performed an experimental study. "
01/01/2015 - "Our results open new role of helixor A as an imune modulation therapy, or in combination with hormonal agents, for the treatment of endometriosis."
01/01/2015 - "Effect of helixor A on natural killer cell activity in endometriosis."
01/01/2015 - "A significant difference in cytotoxicity was observed between the control cells and stage III/IV endometriosis, consistent with a significant decrease in the cytotoxicity of NK cells in advanced stages of endometriosis; these levels increased significantly after treatment with helixor A; 78.30% vs. 86.40% (p=0.003) in stage I/II endometriosis, and 73.67% vs. 84.54% (p=0.024) in stage III/IV. The percentage of cells expressing CD107a was increased significantly in each group after helixor A treatment; 0.59% vs. 1.10% (p=0.002) in stage I/II endometriosis, and 0.79% vs. 1.40% (p=0.014) in stage III/IV. Helixor A directly influenced NK-cell cytotoxicity through direct induction of CD107a expression. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2008 - "Complementary treatment with the sME HELIXOR proved to be beneficial for breast cancer patients since it significantly improved quality of life and significantly reduced persistant signs/symptoms of the disease/treatment during the validated aftercare period of approximately five years."
01/01/2008 - "To investigate the safety and efficacy of complementary treatment of breast cancer patients with the standardized mistletoe extract (sME) HELIXOR in routine practice during aftercare through a multicenter comparative epidemiological cohort study with 53 randomly selected hospitals/practices representatively distributed in Germany, including oncologists, gynaecologists and general practitioners. "
01/01/2007 - "Helixor mistletoe preparations and ML-1 have cytotoxic activity and do not stimulate tumor cell proliferation in vitro which is in accordance with previous scientifically based observations on aqueous mistletoe extracts."
03/06/1990 - "In addition, Helixor supposedly bridges the dramatic gap between conventional and natural treatment of cancer in that it exerts both a selective cancerostatic and an immunostimulatory effect. "
03/06/1990 - "[Helixor--mistletoe preparation for cancer therapy. "
03/01/2015 - "A total of 123 cancer patients received 862 IT mistletoe injections (preparations from Abnoba, Helixor and Iscucin). "
04/01/1997 - "In a recent study, 20 consecutive cancer patients with malignant pleural effusions were treated intrapleurally with the mistletoe extract Helixor. "
|4.||Malignant Pleural Effusion
|2.||Interleukin-6 (Interleukin 6)
|3.||Interleukin-1 (Interleukin 1)
|6.||viscum album peptide (Iscador)